Relative Wirksamkeit und Verträglichkeit von Etoricoxib, Celecoxib und Naproxen bei der Behandlung von Osteoarthritis

Eine bayessche Netzwerkmetaanalyse randomisiert-kontrollierter Studien auf Basis von Patientenausschlüssen

Translated title of the contribution: Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis: A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal

Gwan Gyu Song, Young Ho Seo, Jae Hoon Kim, Sungjae Choi, Jong Dae Ji, Young Ho Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aims: This study aimed to assess the relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen at recommended dosages in patients with osteoarthritis (OA). Methods: Randomized controlled trials (RCTs) examining the efficacy and tolerability of etoricoxib 30–60 mg, celecoxib 200–400 mg, and naproxen 1000 mg, based on the number of patient withdrawals among those with OA, were included in this network meta-analysis. We performed a Bayesian random-effects network meta-analysis to combine direct and indirect evidence from the RCTs. Results: Eight RCTs, including 5,942 patients, met the inclusion criteria. The proportion of patient withdrawals due to lack of efficacy was significantly lower in the etoricoxib 30–60 mg (OR 0.21, 95 % CrI 0.12–0.38), celecoxib 200–400 mg (OR 0.29, 95 % CrI 0.18–0.47), and naproxen 1000 mg (OR 0.31, 95 % CrI 0.18–0.51) groups than in the placebo group. The number of patient withdrawals due to lack of efficacy tended to be lower in the etoricoxib 30–60 mg group than in the naproxen 1000 mg and celecoxib 200–400 mg groups, although they did not reach statistical significance (OR 0.68, 95 % CrI 0.36–1.33 and OR 0.70, 95 % CrI 0.38–1.37, respectively). Ranking probabilities based on the surface under the cumulative ranking curve (SUCRA) indicated that etoricoxib 30–60 mg had the highest probability of being the best treatment based on the number of withdrawals due to lack of efficacy (SUCRA = 0.9168) followed by celecoxib 200–400 mg (SUCRA = 0.5659), naproxen 1000 mg (SUCRA = 0.5171), and placebo (SUCRA = 0.000189). With respect to tolerability, the number of withdrawals due to adverse events was not significantly different among etoricoxib, celecoxib, naproxen, and placebo, although it tended to be lower with etoricoxib and placebo. Conclusions: Etoricoxib 30–60 mg, celecoxib 200–400 mg, and naproxen 1000 mg were more efficacious than placebo. However, there was no significant difference in efficacy and tolerability between the medications.

Original languageGerman
Pages (from-to)508-516
Number of pages9
JournalZeitschrift fur Rheumatologie
Volume75
Issue number5
DOIs
Publication statusPublished - 2016 Jun 1

Fingerprint

etoricoxib
Celecoxib
Naproxen
Osteoarthritis
Randomized Controlled Trials
Placebos
Therapeutics
Network Meta-Analysis

Keywords

  • Celecoxib
  • Etoricoxib
  • Meta-analysis
  • Naproxen
  • Osteoarthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

@article{4c192194274b44e1aa71cfeb4ca5aabf,
title = "Relative Wirksamkeit und Vertr{\"a}glichkeit von Etoricoxib, Celecoxib und Naproxen bei der Behandlung von Osteoarthritis: Eine bayessche Netzwerkmetaanalyse randomisiert-kontrollierter Studien auf Basis von Patientenausschl{\"u}ssen",
abstract = "Aims: This study aimed to assess the relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen at recommended dosages in patients with osteoarthritis (OA). Methods: Randomized controlled trials (RCTs) examining the efficacy and tolerability of etoricoxib 30–60 mg, celecoxib 200–400 mg, and naproxen 1000 mg, based on the number of patient withdrawals among those with OA, were included in this network meta-analysis. We performed a Bayesian random-effects network meta-analysis to combine direct and indirect evidence from the RCTs. Results: Eight RCTs, including 5,942 patients, met the inclusion criteria. The proportion of patient withdrawals due to lack of efficacy was significantly lower in the etoricoxib 30–60 mg (OR 0.21, 95 {\%} CrI 0.12–0.38), celecoxib 200–400 mg (OR 0.29, 95 {\%} CrI 0.18–0.47), and naproxen 1000 mg (OR 0.31, 95 {\%} CrI 0.18–0.51) groups than in the placebo group. The number of patient withdrawals due to lack of efficacy tended to be lower in the etoricoxib 30–60 mg group than in the naproxen 1000 mg and celecoxib 200–400 mg groups, although they did not reach statistical significance (OR 0.68, 95 {\%} CrI 0.36–1.33 and OR 0.70, 95 {\%} CrI 0.38–1.37, respectively). Ranking probabilities based on the surface under the cumulative ranking curve (SUCRA) indicated that etoricoxib 30–60 mg had the highest probability of being the best treatment based on the number of withdrawals due to lack of efficacy (SUCRA = 0.9168) followed by celecoxib 200–400 mg (SUCRA = 0.5659), naproxen 1000 mg (SUCRA = 0.5171), and placebo (SUCRA = 0.000189). With respect to tolerability, the number of withdrawals due to adverse events was not significantly different among etoricoxib, celecoxib, naproxen, and placebo, although it tended to be lower with etoricoxib and placebo. Conclusions: Etoricoxib 30–60 mg, celecoxib 200–400 mg, and naproxen 1000 mg were more efficacious than placebo. However, there was no significant difference in efficacy and tolerability between the medications.",
keywords = "Celecoxib, Etoricoxib, Meta-analysis, Naproxen, Osteoarthritis",
author = "Song, {Gwan Gyu} and Seo, {Young Ho} and Kim, {Jae Hoon} and Sungjae Choi and Ji, {Jong Dae} and Lee, {Young Ho}",
year = "2016",
month = "6",
day = "1",
doi = "10.1007/s00393-015-0023-9",
language = "German",
volume = "75",
pages = "508--516",
journal = "Zeitschrift fur Rheumatologie",
issn = "0340-1855",
publisher = "D. Steinkopff-Verlag",
number = "5",

}

TY - JOUR

T1 - Relative Wirksamkeit und Verträglichkeit von Etoricoxib, Celecoxib und Naproxen bei der Behandlung von Osteoarthritis

T2 - Eine bayessche Netzwerkmetaanalyse randomisiert-kontrollierter Studien auf Basis von Patientenausschlüssen

AU - Song, Gwan Gyu

AU - Seo, Young Ho

AU - Kim, Jae Hoon

AU - Choi, Sungjae

AU - Ji, Jong Dae

AU - Lee, Young Ho

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Aims: This study aimed to assess the relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen at recommended dosages in patients with osteoarthritis (OA). Methods: Randomized controlled trials (RCTs) examining the efficacy and tolerability of etoricoxib 30–60 mg, celecoxib 200–400 mg, and naproxen 1000 mg, based on the number of patient withdrawals among those with OA, were included in this network meta-analysis. We performed a Bayesian random-effects network meta-analysis to combine direct and indirect evidence from the RCTs. Results: Eight RCTs, including 5,942 patients, met the inclusion criteria. The proportion of patient withdrawals due to lack of efficacy was significantly lower in the etoricoxib 30–60 mg (OR 0.21, 95 % CrI 0.12–0.38), celecoxib 200–400 mg (OR 0.29, 95 % CrI 0.18–0.47), and naproxen 1000 mg (OR 0.31, 95 % CrI 0.18–0.51) groups than in the placebo group. The number of patient withdrawals due to lack of efficacy tended to be lower in the etoricoxib 30–60 mg group than in the naproxen 1000 mg and celecoxib 200–400 mg groups, although they did not reach statistical significance (OR 0.68, 95 % CrI 0.36–1.33 and OR 0.70, 95 % CrI 0.38–1.37, respectively). Ranking probabilities based on the surface under the cumulative ranking curve (SUCRA) indicated that etoricoxib 30–60 mg had the highest probability of being the best treatment based on the number of withdrawals due to lack of efficacy (SUCRA = 0.9168) followed by celecoxib 200–400 mg (SUCRA = 0.5659), naproxen 1000 mg (SUCRA = 0.5171), and placebo (SUCRA = 0.000189). With respect to tolerability, the number of withdrawals due to adverse events was not significantly different among etoricoxib, celecoxib, naproxen, and placebo, although it tended to be lower with etoricoxib and placebo. Conclusions: Etoricoxib 30–60 mg, celecoxib 200–400 mg, and naproxen 1000 mg were more efficacious than placebo. However, there was no significant difference in efficacy and tolerability between the medications.

AB - Aims: This study aimed to assess the relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen at recommended dosages in patients with osteoarthritis (OA). Methods: Randomized controlled trials (RCTs) examining the efficacy and tolerability of etoricoxib 30–60 mg, celecoxib 200–400 mg, and naproxen 1000 mg, based on the number of patient withdrawals among those with OA, were included in this network meta-analysis. We performed a Bayesian random-effects network meta-analysis to combine direct and indirect evidence from the RCTs. Results: Eight RCTs, including 5,942 patients, met the inclusion criteria. The proportion of patient withdrawals due to lack of efficacy was significantly lower in the etoricoxib 30–60 mg (OR 0.21, 95 % CrI 0.12–0.38), celecoxib 200–400 mg (OR 0.29, 95 % CrI 0.18–0.47), and naproxen 1000 mg (OR 0.31, 95 % CrI 0.18–0.51) groups than in the placebo group. The number of patient withdrawals due to lack of efficacy tended to be lower in the etoricoxib 30–60 mg group than in the naproxen 1000 mg and celecoxib 200–400 mg groups, although they did not reach statistical significance (OR 0.68, 95 % CrI 0.36–1.33 and OR 0.70, 95 % CrI 0.38–1.37, respectively). Ranking probabilities based on the surface under the cumulative ranking curve (SUCRA) indicated that etoricoxib 30–60 mg had the highest probability of being the best treatment based on the number of withdrawals due to lack of efficacy (SUCRA = 0.9168) followed by celecoxib 200–400 mg (SUCRA = 0.5659), naproxen 1000 mg (SUCRA = 0.5171), and placebo (SUCRA = 0.000189). With respect to tolerability, the number of withdrawals due to adverse events was not significantly different among etoricoxib, celecoxib, naproxen, and placebo, although it tended to be lower with etoricoxib and placebo. Conclusions: Etoricoxib 30–60 mg, celecoxib 200–400 mg, and naproxen 1000 mg were more efficacious than placebo. However, there was no significant difference in efficacy and tolerability between the medications.

KW - Celecoxib

KW - Etoricoxib

KW - Meta-analysis

KW - Naproxen

KW - Osteoarthritis

UR - http://www.scopus.com/inward/record.url?scp=84954307109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954307109&partnerID=8YFLogxK

U2 - 10.1007/s00393-015-0023-9

DO - 10.1007/s00393-015-0023-9

M3 - Article

VL - 75

SP - 508

EP - 516

JO - Zeitschrift fur Rheumatologie

JF - Zeitschrift fur Rheumatologie

SN - 0340-1855

IS - 5

ER -